Doctors condemn NICE's guidance on leukaemia drugBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7350.1352/a (Published 08 June 2002) Cite this as: BMJ 2002;324:1352
- Susan Mayor
Leukaemia specialists in the United Kingdom are actively campaigning to overturn draft guidance issued by the National Institute for Clinical Excellence (NICE) that the signal transduction inhibitor imatinib (Glivec) should be used only in NHS patients with advanced chronic myeloid leukaemia.
The NICE appraisal consultation document recommends imatinib for the treatment of patients with accelerated phase chronic myeloid leukaemia (CML). However, it did not recommend its use for …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial